Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Cardiac Resynchronization Therapy

  • Author: Adam S Budzikowski, MD, PhD, FHRS; Chief Editor: Richard A Lange, MD, MBA  more...
 
Updated: Dec 17, 2014
 

Background

Cardiac resynchronization therapy (CRT), also known as biventricular pacing or multisite ventricular pacing, involves simultaneous pacing of the right ventricle (RV) and the left ventricle (LV). To this end, a coronary sinus lead is placed for LV pacing in addition to a conventional RV endocardial lead (with or without a right atrial [RA] lead). (See Permanent Pacemaker Insertion.)

The basic goal of CRT is to restore LV synchrony in patients with dilated cardiomyopathy and a widened QRS, which is predominantly a result of left bundle branch block, in order to improve the mechanical functioning of the LV.

Guidelines from the European Society of Cardiology (ESC), developed in collaboration with the European Heart Rhythm Association (EHRA), indicate that choices about pacing, as well as about the use of implantable cardioverter-defibrillators (ICDs) and CRT, should be influenced by the specific qualities and clinical manifestations of bradyarrhythmias.[2, 3]

The guidelines identify 3 subsets of patients[2, 3] : (1) those with persistent bradycardia (including sinus node disease and atrioventricular [AV] block); (2) those with electrocardiographically documented intermittent bradycardia; and (3) those with suspected (ie, electrocardiographically undocumented) bradycardia.

Appropriate pacing choices are made based on this classification, with a similar scheme used for decisions regarding treatment with CRT. Patients with persistent bradycardia will likely require pacing, while those with atrial defibrillation may, depending on their clinical features, be treated with pacing, CRT, or AV junction ablation.[2, 3]

Next

Practice Essentials

The basic goal of cardiac resynchronization therapy (CRT) is to restore synchrony of the left ventricle in patients with dilated cardiomyopathy and a widened QRS. This involves placement of a coronary sinus (CS) lead for left ventricular (LV) pacing, in addition to placement of a conventional right ventricular (RV) endocardial lead, with or without a (right atrial) lead.

Equipment

A pacemaker is an electronic device, approximately the size of a pocket watch, that senses intrinsic heart rhythms and provides electrical stimulation when indicated. Cardiac pacing can be either temporary or permanent.

Permanent pacing is most commonly accomplished through transvenous placement of leads to the endocardium (ie, right atrium or ventricle) or epicardium (ie, the LV surface via the CS), which are subsequently connected to a pacing generator placed subcutaneously in the infraclavicular region.

CRT is a specialized type of pacemaker therapy that provides biventricular pacing. This is carried out with or without the use of an implantable cardioverter-defibrillator (ICD), a device employed for treatment and prophylaxis in patients at risk for ventricular tachycardia (VT) or ventricular fibrillation (VF).

See Periprocedural Care and Devices for more detail.

Technique

Access to the CS for implantation of the LV lead may be achieved via the axillary, subclavian, or cephalic vein.

To facilitate stable LV lead placement, it is practical first to place the RV pacing lead and then to advance the LV lead into the CS branch, leaving the sheath in place. After the RA lead is positioned, the LV lead guiding sheath is removed, and the LV lead is sutured in place.

RV lead

In most cases, the delivery system sheath is passed over a guidewire into the RA and then advanced slowly into the RV, where 90-180° of counterclockwise rotation is subsequently applied while the sheath is gently withdrawn and then advanced. This maneuver generally brings the sheath to the CS or the vicinity of the CS os, allowing easy cannulation of the CS with a guidewire.

LV lead

Although it may be possible to place the LV lead without knowing the anatomy of the CS and its branches, it is prudent to obtain a CS phlebogram to direct the selection and placement of this lead.

Successful resynchronization can be achieved with placement of the LV lead in almost any CS branch, provided that the site is in the proximal third to the middle third of the LV.[1]

Several techniques have been described for branch cannulation, including the following:

  • Branches with acute-angle origins can often be cannulated with an angioplasty wire without any difficulty
  • If a branch originating at a right or obtuse angle is difficult to cannulate, an inner catheter may be inserted near the preselected branch so that the guidewire can be advanced into the branch; once this is accomplished, the catheter may be exchanged for a packing lead while the wire position is maintained
  • Alternatively, in such problematic cases, a larger-lumen inner catheter may be used to allow delivery of the pacing lead; this technique has been simplified by using a lead with an exaggerated curve, through which a stylet or angioplasty guidewire is advanced to direct the lead tip into the appropriate venous branch

See Technique for more detail.

Previous
Next

Indications and Contraindications

Randomized clinical trials have confirmed the effectiveness of CRT for the following purposes:

  • Improving cardiac hemodynamics and symptoms [4, 5]
  • Preventing hospitalization
  • Improving mortality [6] as compared with conventional therapy in patients with advanced heart failure symptoms and severe left ventricular dysfunction

Evidence suggests that CRT may even be beneficial in patients with mildly symptomatic heart failure (New York Heart Association [NYHA] class II).[7, 8, 6] A study of 659 heart failure patients who underwent successful CRT found the procedure safe to use in patients with clinically significant mitral regurgitation (MR). At 12-month followup, patients with more than mild MR had comparable results to patients with mild or no MR.[9] Most of the benefits appear to be associated with the presence of left bundle branch block (LBBB) on electrocardiography (ECG); the longer the QRS duration (particularly >150 msec), the more beneficial CRT is likely to be.[10]

In light of this and other accumulating evidence, the American College of Cardiology (ACC), American Heart Association (AHA), and Heart Rhythm Society (HRS) modified the Class I indication for CRT to include not only patients with NYHA class III and IV symptoms, but also those with NYHA class II symptoms and left-bundle-branch block with a QRS duration that is greater than or equal to 150 ms.[11]

Results from a retrospective study that evaluated long-term outcomes in patients with ambulatory NYHA class III and IV heart failure who underwent CRT over a 4-year period (2003-2007) indicate that, despite inferior outcomes for those with ambulatory NYHA class IV heart relative to those with NYHA class III symptoms, the survival of patients in both groups are parallel over extended follow-up (mean follow-up, 5.0 +/- 2.5 y).[12] Ambulatory NYHA class IV status was an independent factor for poor long-term outcomes, with a 40% survival free of left ventricular assist device (LVAD) or heart transplantation at 5 years.

In patients with other forms of conduction disturbance (eg, right bundle branch block [RBBB] or RV pacing), CRT is of questionable utility and therefore cannot be recommended at this time.

Previous
 
 
Contributor Information and Disclosures
Author

Adam S Budzikowski, MD, PhD, FHRS Assistant Professor of Medicine, Division of Cardiovascular Medicine, Electrophysiology Section, State University of New York Downstate Medical Center, University Hospital of Brooklyn

Adam S Budzikowski, MD, PhD, FHRS is a member of the following medical societies: European Society of Cardiology, Heart Rhythm Society

Disclosure: Received consulting fee from Boston Scientific for speaking and teaching; Received honoraria from St. Jude Medical for speaking and teaching; Received honoraria from Zoll for speaking and teaching.

Coauthor(s)

James K Gabriels, MD, MSc State University of New York Downstate Medical School

Disclosure: Nothing to disclose.

Chief Editor

Richard A Lange, MD, MBA President, Texas Tech University Health Sciences Center, Dean, Paul L Foster School of Medicine

Richard A Lange, MD, MBA is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association, Association of Subspecialty Professors

Disclosure: Nothing to disclose.

References
  1. Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation. 2011 Mar 22. 123(11):1159-66. [Medline].

  2. Boggs W. Choose Cardiac Therapy Based on Arrhythmia Presentation, Says New Guideline. Medscape. Jul 8 2013. Available at http://www.medscape.com/viewarticle/807444. Accessed: July 16, 2013.

  3. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013 Jun 24. [Medline].

  4. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20. 350(21):2140-50. [Medline].

  5. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003 May 28. 289(20):2685-94. [Medline].

  6. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010 Dec 16. 363(25):2385-95. [Medline].

  7. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009 Oct 1. 361(14):1329-38. [Medline].

  8. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 2. 52(23):1834-43. [Medline].

  9. Boriani G, Gasparini M, Landolina M, Lunati M, Biffi M, Santini M, et al. Impact of Mitral Regurgitation on the Outcome of Patients Treated with CRT-D: Data from the InSync ICD Italian Registry. Pacing Clin Electrophysiol. 2012 Feb. 35(2):146-154. [Medline].

  10. Zareba W, Klein H, Cygankiewicz I, et al. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Mar 15. 123(10):1061-72. [Medline].

  11. Tracy CM, Epstein AE, Darbar D, Dimarco JP, Dunbar SB, Estes NA 3rd, et al. 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012 Sep 10. [Medline].

  12. Rickard J, Bassiouny M, Tedford RJ, et al. Long-term outcomes in patients with ambulatory New York Heart Association class III and IV heart failure undergoing cardiac resynchronization therapy. Am J Cardiol. 2015 Jan 1. 115(1):82-5. [Medline].

  13. Shetty AK, Duckett SG, Bostock J, Rosenthal E, Rinaldi CA. Use of a quadripolar left ventricular lead to achieve successful implantation in patients with previous failed attempts at cardiac resynchronization therapy. Europace. 2011 Jul. 13(7):992-6. [Medline]. [Full Text].

  14. Dhillon PS, Gallagher MM. Femoral vein implantation with subclavian vein pullthrough for left ventricular lead placement. Europace. 2010 Aug. 12(8):1193-4. [Medline].

  15. Jourdier L, Swinburn J, Roberts D, Clague J. Implantation of a biventricular implantable cardioverter defibrillator via the femoral vein. Pacing Clin Electrophysiol. 2007 Apr. 30(4):571-2. [Medline].

  16. Douglas D. RF Ablation May Aid Cardiac Resynchronization. Medscape Medical News. Available at http://www.medscape.com/viewarticle/771616. Accessed: October 15, 2012.

  17. Lakkireddy D, Di Biase L, Ryschon K, Biria M, Swarup V, Reddy YM, et al. Radiofrequency ablation of premature ventricular ectopy improves the efficacy of cardiac resynchronization therapy in nonresponders. J Am Coll Cardiol. 2012 Oct 16. 60(16):1531-9. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.